Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
120 participants
INTERVENTIONAL
2020-08-01
2021-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prohepcidin, Inflammation and Iron Homeostasis in Hemodialysis Patients With Chronic Hepatitis C
NCT01272479
ST-2; a Non-invasive Fibrosis Marker for Chronic Hepatitis B
NCT01633554
Albumin Modifications as Early Biomarkers of Chronic Liver Diseases
NCT06318949
Assessment of Endocan Serum Levels in Patients With Behcet Disease
NCT03853135
Cytokines and the Risk of Infection in Liver Cirrhosis
NCT00857181
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
DIAGNOSTIC
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Chronic Hepatitis B
Measurement of serum regucalcin level
Serum regucalcin level
During routine outpatient controls, serum regucalcin level will be measured from the rest of the blood taken for examinations.
Healthy Volunteers
Measurement of serum regucalcin level
Serum regucalcin level
During routine outpatient controls, serum regucalcin level will be measured from the rest of the blood taken for examinations.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Serum regucalcin level
During routine outpatient controls, serum regucalcin level will be measured from the rest of the blood taken for examinations.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Not having a known history of liver disease who applied to our outpatient clinic for other reasons
* Having a liver biopsy
* ≥18 years
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Konya Meram State Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fatma Çölkesen
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Konya Training and Research Hospital
Konya, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Wei X, Yu H, Zhao P, Xie L, Li L, Zhang J. Serum regucalcin is a useful indicator of liver injury severity in patients with hepatitis B virus-related liver diseases. Braz J Med Biol Res. 2019 Sep 30;52(10):e8845. doi: 10.1590/1414-431X20198845. eCollection 2019.
Yamaguchi M, Isogai M, Shimada N. Potential sensitivity of hepatic specific protein regucalcin as a marker of chronic liver injury. Mol Cell Biochem. 1997 Feb;167(1-2):187-90. doi: 10.1023/a:1006859121897.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10542
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.